Shares of Jazz Pharmaceuticals JAZZ moved higher by 7.9% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 5.12% year over year to $4.31, which beat the estimate of $4.08.
Revenue of $600,888,000 rose by 11.75% from the same period last year, which beat the estimate of $577,580,000.
Looking Ahead
The upcoming fiscal year's EPS expected to be between $12.20 and $13.00.
The upcoming fiscal year's revenue expected to be between $2,320,000,000 and $2,380,000,000.
How To Listen To The Conference Call
Date: Nov 02, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/48nkgo6h
Price Action
Company's 52-week high was at $156.26
52-week low: $86.88
Price action over last quarter: Up 28.44%
Company Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
